middle.news
FDA Confirms Single Phase 3 Trial Pathway for Alterity’s ATH434 in MSA
9:44am on Tuesday 7th of July, 2026 AEST
•
Biotechnology
Read Story
FDA Confirms Single Phase 3 Trial Pathway for Alterity’s ATH434 in MSA
9:44am on Tuesday 7th of July, 2026 AEST
Key Points
FDA endorses single pivotal Phase 3 trial plus confirmatory evidence
Phase 3 design includes 200 patients, 12-month treatment, functional endpoints
ATH434 targets iron accumulation and α-synuclein pathology in MSA
Positive Phase 2 data underpin confirmatory evidence for approval
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE